Clinicians Still Have Concerns Regarding Melanoma Treatment Options
the Cancer Therapy Advisor take:
Two new targeted systemic therapies have been recently introduced as possible treatment options for advanced melanoma, according to an article published online in the European Journal of Cancer Care.
Participants in this study included 343 oncologists who completed online surveys between August and November 2012 (in 11 countries) and March and April 2013 (in another country), following the introduction of the two new treatment agents.
The authors analyzed the results of the surveys and found 23 clinical issues of concern across all countries. Of these 23 issues, the most common were identified as being drug toxicity and tolerability. The second most common was limited treatment effectiveness, followed by limited treatment options.
The findings of the study state that clinical professionals still have concern regarding the limitations of treatment options available to patients despite the promise of two new agents for treating advanced melanoma.

Two new targeted systemic therapies have been recently introduced as possible treatment options for advanced melanoma.
Related Resources
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Opinion: Understanding the FDA's Take on Cannabidiol
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk